anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Laparoscopic surgery has been used to treat gastric submucosal tumors (SMTs). Laparoscopic and endoscopic cooperative surgery (LECS) has been used when subtotal resection has been difficult, which enabled resection of these tumors. In this study, we reviewed the medical records of patients with gastric SMTs who underwent laparoscopic surgery in our hospital with the aim of reporting the surgical indications, procedures (especially for LECS), and outcomes of surgery. This study involved 55 patients who underwent laparoscopic surgery between April 2014 and March 2021. We classified the patients into two groups: laparoscopy-assisted surgery group (non-LECS group, n = 30) and LECS group (n = 25). LECS was performed in the upper stomach, in the greater curvature of the lower stomach, and in both intraluminal and intramural locations in the middle stomach. Non-LECS was selected for extraluminal and intramural tumors in the greater curvature of the upper stomach. There were no severe complications associated with the operation. There was one postoperative complication in the LECS group. The length of postoperative hospital stay did not significantly differ between the LECS and non-LECS groups. We reported the surgical procedures for gastric SMTs in our hospital. It is essential to make full use of the multiple techniques reported in this article and examine the location of the tumor to avoid excess or insufficient resection. Our review of the present case series allowed us to select the appropriate surgical approach for gastric SMTs based on the lesion location and type of development.
<P>PROBLEM TO BE SOLVED: To provide a clinically applicable siRNA targeting ADAT1 gene.  <P>SOLUTION: This siRNA is a double-stranded siRNA specifically targeting ADAT1 gene and having 21 bases including 19 base pairs and a 3'-terminal overhang having 2 bases, or having a blunt end composed of 27 base pairs. The double-stranded siRNA can mediate an RNAi specific to ADAT1 gene while avoiding off-target effect and interferon response. The siRNA is applicable e.g. in clinical use and is useful in medical and pharmaceutical composition fields having ADAT1 as the target molecule, for example, the medical and pharmaceutical composition fields relating to the treatment of cancers including head and neck cancers.  <P>COPYRIGHT: (C)2009,JPO&INPIT
The phase 1 trial will begin with a dose of 78mg. All treatment arms will administer study drug every 12 hours for up to 14 days (28 doses). Up to 6 infants in this arm will receive the 78mg dose of tobramycin solution for inhalation administered via vibrating mesh nebulizer. During the trial, infants in each treatment arm will undergo blood and tracheal aspirate sampling and respiratory mechanics measurements at pre-specified time points to assess dose safety and potential efficacy. Continuous pulse oximetry monitoring for the duration of the trial will also occur. Clinical data will also be recorded daily throughout the trial in all participants.
Subjects in control clusters will continue to receive usual care from their frontline health workers. After 12 months (primary effectiveness study) control will cross into the intervention for months 12-24.
PURPOSE:To provide the titled composition containing glycyrrhezic acid, quillaia saponin and water as essential components, containing glycyrrhezic acid having pharmacological effects such as anti-inflammatory effect and antiulcer effect, etc. at a high concentration by the solubilization effect of quillaia saponin, and usable safely as a medicine, etc. CONSTITUTION:The objective composition contains glycyrrhezic acid, guillaia saponin and water as essential components, wherein the glycyrrhezic acid is solubilized with quillaia saponin and contained in high concentration. Glycyrrhezic acid is an aglicon of glycyrrhizic acid which is a triterpenoid glycoside existing in the root of Glycyrrhiza glabra, and can be synthesized by hydrolyzing glycyrrhizic acid. Quillaia saponin is a saponin existing in the rosin of Quillaia saponalia mol. The amount of the quillaia saponin necessary for the stable solubilization of glycyrrhezic acid is about >=1pt.(wt.), preferably about 8-40pts. per 1pt. of glycyrrhezic acid.
BACKGROUND: Incorporating chimeric antigen receptor (CAR)-T cell therapy into relapsed or refractory large B-cell lymphoma (rr LBCL) treatment algorithms has yielded remarkable response rates and durable remissions, yet a substantial portion of patients experience progression or relapse. Variations in outcomes across treatment centers may be attributed to different bridging strategies and remission statuses preceding CAR-T cell therapy.
PATIENTS: Twenty-nine consecutive adult patients receiving tisagenlecleucel (tisa-cel) for rr LBCL from December 2019 to February 2023 at Jena University Hospital were analyzed.
RESULTS: The median age was 63, with a median of 3 prior treatments. Twenty patients (69%) were refractory to any systemic therapy before CAR-T cell treatment. Following leukapheresis, 25 patients (86%) received bridging therapy with the majority undergoing chemotherapy (52%) or combined modality therapy (32%). Radiotherapy (RT) was part of the bridging strategy in 44%, with moderately hypofractionated involved site RT (30.0 Gy/2.5 Gy) being applied most frequently (64%). Post-CAR-T infusion, the objective response rate at 30 days was 83%, with 55% achieving complete response. Twelve-month progression-free (PFS) and overall survival (OS) were 60% and 74%, respectively, with a median follow up of 11.1 months for PFS and 17.9 months for OS. Factors significantly associated with PFS were chemotherapy sensitivity pre-leukapheresis and response to bridging.
CONCLUSION: The study underscores the importance of minimal tumor burden at CAR-T initiation, emphasizing the need for suitable bridging regimens. The findings advocate for clinical trials and further real-world analyses to optimize CAR-T cell therapy outcomes by identifying the most effective bridging strategies.
Dyads of healthy Polish adolescents 16-18 y.o., who have sibling with intellectual disability and one of their parent. The parent's participation is necessary to assess the presence of possible disorders in a healthy child.
Improved methods for inhibiting rejection of transplanted cells in an allogeneic or xenogeneic recipient subject are described. The methods involve altering at least one antigen on the surface of a donor cell prior to transplantation to reduce the immunogenicity of the cell in a recipient subject. Preferably, an MHC class I antigen on a donor cell is altered by contacting the cell with a molecule which binds to the antigen, such as an antibody or fragment or derivative thereof. According to the methods of the invention, a recipient subject is also treated with an agent which inhibits T cell activity in the subject. A preferred agent which inhibits T cell activity in the recipient subject is an immunosuppressive drug, such as cyclosporin A. Alternatively, antibodies which deplete T cells or inhibit T cell proliferation in the subject can be used. Typically, following administration of a modified donor cell to an allogeneic or xenogeneic recipient subject, an immunosuppressive drug is administered to the recipient subject for a sufficient time to induce tolerance to the donor cells.
Glucocorticoid (GC) is the main stay of treatment of many rheumatic diseases but is also an important cause of secondary osteoporosis. The long-term use of GCs increases the risk of fragility fracture at a much higher bone mineral density (BMD) than postmenopausal osteoporosis, indicating an additional deleterious effect of GC on bone quality. More than one-third of postmenopausal women receiving GC therapy developed asymptomatic vertebral fractures. A study in general practice reported an increased relative risk of vertebral and hip fractures in chronic GC users, with fracture risk proportional to the daily dose of GC. Another study also confirmed that intermittent use of high-dose GC and the cumulative GC dose was associated with an augmented risk of osteoporotic fracture.

The glycoprotein sclerostin, secreted by the osteocytes under the influence of mechanical loading, inhibits activation of the canonical Wnt pathway involved in osteoblastogenesis and hence suppresses bone formation. Moreover, sclerostin enhances resorption of the bone by stimulating the production of (RANKL) by the osteocytes. Romosozumab (ROMO) is a humanized monoclonal antibody against sclerostin. The landmark RCT has demonstrated efficacy of ROMO (210mg subcutaneously monthly) over placebo in reducing vertebral fractures by 73% at 12 months in 7180 postmenopausal women with osteoporosis of the hip at entry. The suppression of markers of bone resorption and enhancement of markers of bone formation indicates that ROMO has a dual mode of action on the bones. The efficacy of ROMO has also been tested against oral bisphosphonates. A RCT was conducted in 4093 post-menopausal women who were assigned to receive either ROMO (201mg subcutaneously monthly) or oral alendronate (70mg weekly) for 12 months, followed by open-label alendronate for another 12 months. At month 24, a 48% lower risk of new vertebral fractures was observed in the ROMO (6.2%) than the alendronate group (11.9%; p\<0.001). The risk of incident hip fractures was also significantly lower in the ROMO (2%) than alendronate treated patients (3.2%; p=0.02). The frequencies of adverse events and serious adverse events, however, were similar in the two treatment arms.

There are no data regarding the efficacy of ROMO in GC-induced osteoporosis. Comparative study on the efficacy of ROMO and denosumab in post-menopausal osteoporosis is also not yet available in the literature. This prompts the current pilot study to compare the efficacy of ROMO with denosumab in high-risk patients receiving long-term GCs.
PURPOSE:The titled pharmaceutical, containing a substance FK-565, and capable of enhancing further the physiological activity. CONSTITUTION:A pharmaceutical, containing liposome, and prepared by dissolving a natural phospholipid, e.g. egg yolk lecithin, soybean lecithin or sphingomyelin or phosphatidyl serine, or a synthetic phospholipid, e.g. distearoylphosphatidyl choline or dipalmitoylphosphatidyl choline, capable of forming a liposome membrane, in an organic solvent, e.g. chloroform, introducing the resultant solution into a suitable vessel, distilling away the solvent under reduced pressure, forming a thin membrane on the inner surface of the vessel, introducing an aqueous solution of a substance FK-565 thereinto, and shaking or treating the resultant mixture with ultrasonic waves to give a suspension of the liposome (fine particles). The resultant liposome can be isolated by means of centrifugation, etc. The substance FK-565 has the antitumor and phylactic action.
FIELD: chemistry; biochemistry. ^ SUBSTANCE: invention relates to biotechnology and pharmaceutical industry and can be used in production and use of medical immunoboiological drugs and biologically active food additives. The immunobiological antiallergic agent contains a consortium of microorganisms of the Lactobacillus acidophilus strains, which includes the Lactobacillus acidophilus NKJC strain, collection No. 220, stored in the State collection of microorganisms of normal flora of the G.N. Gabrichevsky Federal State Research Institution of the Moscow Institute of Epidemiology and Microbiology Rospotrebnadzor, Lactobacillus acidophilus JCH strain, collection No. 221, stored in the State collection of microorganisms of normal flora of the G.N. Gabrichevsky Federal State Research Institution of the Moscow Institute of Epidemiology and Microbiology Rospotrebnadzor,and the Lactobacillus acidophilus KAA strain, collection No. 223, stored in the State collection of microorganisms of normal flora of the G.N. Gabrichevsky Federal State Research Institution of the Moscow Institute of Epidemiology and Microbiology Rospotrebnadzor. The agent contains a biomass of the said consortium of microorganisms of Lactobacillus acidophilus strains in a culture medium or supernatant fluid, as well as target additives. The agent is made in form of a suspension or a cream, or an ointment or a paste or a mask. The agent is meant for use in preventing or treating skin defects, dermatitis, allergic diseases, pseudoallergic diseases without comorbidity or combined with infectious aetiology diseases, intestinal dysbacteriosis. ^ EFFECT: invention provides high efficiency of antiallergic effect of immunobiological agents based on lactobacillus. ^ 16 cl, 6 ex
OBJECTIVES: The study aimed to investigate the relationship between perceived stress level and death anxiety in individuals with COPD.
METHOD: It was planned with a descriptive and relational screening design. It was carried out with the participation of 132 patients diagnosed with COPD. The study data were collected through Patient Information Form, Perceived Stress Scale, and Death Anxiety Scale. Descriptive statistics and multiple regression analysis were used in data analysis.
RESULTS: The COPD patients' total perceived stress scale and perceived insufficient self-efficacy and perceived stress/distress subscale mean scores were found as 32.75 ± 5.32, 15.81 ± 3.60, and 16.93 ± 2.97, respectively. The patients' Anxiety total scale mean score was determined to be 6.96 ± 3.40. A positive and statistically significant relationship was found between COPD patients' Perceived Stress total scale mean score and their Death Anxiety Scale mean score (F = 4.332, p < 0.05).
CONCLUSION: Perceived stress level of COPD patients was found to be at a high level, while their death anxiety level was determined as moderate. It was also determined that as perceived stress levels of the patients increased, their death anxiety levels also increased.
Time-restricted feeding is known to ameliorate obesity in young mice. However, evaluation of its effect in old age is still lacking. The current work aims to investigate the effects of time-restricted feeding on treating pre-existing obesity in old animals. The study utilized middle-aged and old high fat diet-induced obese mice and subjected them to 8 h daily time-restricted feeding. Aged obese mice did not lose fat mass but lost lean mass after 8 weeks of treatment. In addition, time-restricted feeding reduced adiposity in brown adipose tissue, reversed excessive hepatic lipid accumulation, and improved glucose homeostasis in middle-aged and old obese mice. Mechanistic studies show that these metabolic benefits were mediated by transcriptional downregulation of essential genes responsible for hepatic adipogenesis and adipose tissue chronic inflammation. These results demonstrate that time-restricted feeding improves metabolic health and has beneficial effects in combating diet-induced obesity in aged obese mice. KEY POINTS: Contrary to in young obese mice, in old obese mice time-restricted feeding did not significantly reduce body fat but decreased lean mass. Time-restricted feeding reduced adipose tissue inflammation, reversed fatty liver, and improved glucose homeostasis in aged mice with diet-induced obesity. Time-restricted feeding is effective in improving metabolic homeostasis in aged mice, but less effective in terms of reducing obesity. Future studies should investigate the underlying mechanism of how ageing impaired intermittent fasting induced fat loss.
Plinabulin is a microtubule destabilizing agent (MDA) that inhibits the polymerization of tubulin monomers with resultant vascular disrupting properties. Plinabulin inhibits tumor growth by targeting both angiogenesis and tumor vasculature as well as directly by inducing apoptosis via the Ras-JNK pathway. It also may activate anti-tumor immunity via inducing maturation of dendritic cells (DC) and triggering release of pro-inflammatory cytokines. Plinabulin could therefore have a synergic anti-tumor effect when combined with immune-checkpoint inhibitors. This hypothesis has been confirmed in a murine model bearing subcutaneous MC38 colon cancers using other MDAs, including ansamitocin P3, which induces DC maturation similar to that of plinabulin. Plinabulin has been tested in a randomized phase 2 trial in combination of docetaxel and showed similar response rate to that of docetaxel alone, but with a significantly longer duration of response.

Nivolumab is an inhibitor of the programmed cell death receptor-1 checkpoint pathway (PD-1) that has superior activity in NSCLC, regardless of tumor histology, comparing to standard of care. In this study, we plan to combine nivolumab with escalating doses of plinabulin to determine the maximum tolerated dose (MTD) and /or recommended Phase 2 dose (RP2D) of the combination. An expansion cohort will be enrolled at RP2D to further assess toxicities and to evaluate preliminary anti-tumor activity.

This is a single-center, phase 1 dose finding trial of plinabulin, combining with FDA approved dose of nivolumab, using a 3+3 design in patients with metastatic NSCLC who progressed after chemotherapy, including a platinum-containing regimen. Patients will receive plinabulin at escalating doses in combination with nivolumab. Doses of plinabulin and nivolumab will be administered as intravenous infusions in 4-week cycles. Patients will receive both medications on Days 1 and 15 and additional dose of plinabulin on Day 8. Plinabulin will be administered 60 minutes after the completion of nivolumab.
Embodiments of the present invention include a system for adjusting the cannabinoid dosage of transdermal patches in a transdermal patch kit to treat specific ailments. The methods include cannabinoid treatment dose calculation and selection of one or more transdermal patches. The transdermal patch kit contains a plurality of transdermal patches containing different dosages of individual cannabinoids, or mixtures of cannabinoids at different ratios, or mixtures of cannabinoids and other cannabis components at different ratios. A mobile application is designed to calculate the dosage relative to the need of the user and select the transdermal patch or patches required to deliver the dosage. The user may choose one or several cannabis transdermal patch dose units specific to individual ailments with a controlled dosage of cannabis components. In some embodiments, the user can treat specific ailments such as inflammation.
Participants in two age groups will receive moderate (three sets of per exercise per session) and low-volume (one set of resistance per session) training allocated to either right or left upper- and lower extremities. A total of 24 sessions will be performed over 10-12 weeks.
Once patient has been randomized, if placed in the anatomically-guided injection group, the medial band of the plantar fascia origin on the calcaneus will be palpated and marked approximately. In the clinical setting, a sham ultrasound machine will be utilized to "locate" the plantar fascia keeping the patient blinded to the treatment modality. The area will then be prepped with alcohol to the medial heel and utilizing a medial approach, an injection of 0.5 cc 0.5% bupivacaine, 0.5 cc dexamethasone and 0.25 cc triamcinolone acetamide 40 mg/mL will be administered into the area surrounding the plantar fascia. The area will then be cleaned will alcohol and dressed with a small elastic bandage.
The invention relates to an absorbable degradatable starch hemostatic material. Involved starch is modified starch and includes one or more of carboxymethyl starch and hydroxypropyl starch. The starch hemostatic material includes one or more forms of hemostatic micro-particles, a hemostatic membrane and a hemostatic sponge. The preparation method includes processes of inactivating and devirusing, and the purposes comprise that the prepared hemostatic material is safe and effective and has an excellent hemostatic effect and generates no heat source reaction in clinical application. The preparation method also includes a granulating process of the hemostatic particles and a vacuum freeze-drying process of other forms of hemostatic materials. The prepared hemostatic material has excellent biocompatibility, can be absorbed and degraded in vivo, is non-toxic, has no stimulation, has flexible forms, can be directly used in various complicated bloody wound surfaces, absorbs moisture in blood, aggregates coagulation factors, platelets, fibrous protein sources and red corpuscles in the blood to the wound surfaces, and plays roles in closing hemostasis, preventing tissue adhesion and promoting tissue healing.
The 3 FDA-approved CDK4, 6 inhibitors, palbociclib, ribociclib, and abemciclib, all provided progression-free survival benefits when combined with endocrine therapy in advanced ER+/HER2- breast cancer. But, not all of them provided overall survival benefit in the same setting. One of the proposed mechanisms that influence the overall survival difference is from the different influence of the 3 CDK4, 6 inhibitors on tumor microenvironment and/ or immune system. However, there was no head-to-head comparison of the 3 CDK4, 6 inhibitors in the same study. Neoadjuvant therapy provides a window to obtain tissue samples before treatment, during treatment, and after treatment. We aim to compare the immune modulation effects of palbociclib, ribociclib, and abemaciclib with letrozole in neoadjuvant treatment for ER+/HER2- early breast cancer. We will collect tumor tissue, blood, and stool samples prospectively before treatment, at 2 weeks after treatment, and after 12 weeks of treatment at the time of surgery. Immune modulation effects will be compared between 3 treatment groups from breast tumor RNAseq analysis.
BACKGROUND: In the general intensive care unit (ICU) women receive invasive mechanical ventilation (IMV) less frequently than men. We investigated whether sex differences in the use of IMV also exist in the neurocritical care unit (NCCU), where patients are intubated not only due to respiratory failure but also due to neurological impairment.
METHODS: This retrospective single-centre study included adults admitted to the NCCU of the University Hospital Zurich between January 2018 and August 2021 with neurological or neurosurgical main diagnosis. We collected data on demographics, intubation, re-intubation, tracheotomy, and duration of IMV or other forms of respiratory support from the Swiss ICU registry or the medical records. A descriptive statistics was performed. Baseline and outcome characteristics were compared by sex in the whole population and in subgroup analysis.
RESULTS: Overall, 963 patients were included. No differences between sexes in the use and duration of IMV, frequency of emergency or planned intubations, tracheostomy were found. The duration of oxygen support was longer in women (men 2 [2, 4] vs. women 3 [1, 6] days, p = 0.018), who were more often admitted due to subarachnoid hemorrhage (SAH). No difference could be found after correction for age, diagnosis of admission and severity of disease.
CONCLUSION: In this NCCU population and differently from the general ICU population, we found no difference by sex in the frequency and duration of IMV, intubation, reintubation, tracheotomy and non-invasive ventilation support. These results suggest that the differences in provision of care by sex reported in the general ICU population may be diagnosis-dependent. The difference in duration of oxygen supplementation observed in our population can be explained by the higher prevalence of SAH in women, where we aim for higher oxygenation targets due to the specific risk of vasospasm.